Sonja Fulmer is the Deputy Director for the Digital Health Center of Excellence in the Center for Devices and Radiological Health (CDRH). Dr. Fulmer works to advance and implement new policy approaches to medical device software and digital health technologies to better promote and protect public health. Dr. Fulmer joined the Center for Devices and Radiological Health (CDRH) in 2014 as an AIMBE Scholar to pursue her interest in science policy after earning her doctorate in Chemical and Physical Biology from Vanderbilt University. Dr. Fulmer has held several policy-focused positions in the Office of the Center Director and later as a Policy Advisor in the Office of Policy at CDRH, before joining the Digital Health Center of Excellence.

Kal Patel, MD has over 20 years of experience in pharma, medtech and regulated digital health.

He currently serves as CEO and Co-Founder at BrightInsight, the leading global platform for biopharma and medtech regulated digital health solutions. BrightInsight has raised $166M in financing from world-renowned venture capital firms including General Catalyst, Insight Partners, New Leaf Venture Partners, and Eclipse Ventures, and attracted some of the world’s top biopharma and medtech companies as customers including Sanofi, Novo Nordisk, Roche, AstraZeneca, UCB and CSL Behring, among others.

Prior to founding BrightInsight he was Chief Commercial Officer for Doctor on Demand, now one of the nation’s largest video-medicine provider, with backing from Andreessen Horowitz, Venrock, Google Ventures, and Qualcomm.

Kal founded and built Amgen’s Digital Health business unit where he had end-to-end responsibility for developing and commercializing a portfolio of regulated digital products including connected devices, Software as a Medical Device (SaMD), and algorithms.

Prior to his focus on digital health at Amgen, Kal was the Global Marketing Lead for Enbrel, the company’s leading drug with over $6B in sales, where he created and launched major investments in novel clinical trials, innovative drug delivery devices, improved formulations and differentiated patient support programs. Kal started his Amgen career as Head of Corporate Strategy.

Kal also spent several years at Novartis Pharmaceuticals in various sales, marketing and account leadership roles. He began his professional career at the Boston Consulting Group where he worked for a broad portfolio of Healthcare companies across the U.S. and Europe. He transferred to the company’s Budapest office as part of BCG’s prestigious Ambassador program and was promoted early to Principal. Kal has also served as a Senior Advisor in Digital Health to the Boston Consulting Group where he helped C-level executives at pharma and medtech companies develop and execute digital health strategies.

As Managing Director & General Manager for Fitbit Health Solutions at Google, Amy leads the team working with employers, health plans and health systems to design solutions and programs focused on engagement, positive return on investment and health outcomes. Previously, Amy was Chief Operating Officer of Fitbit Health Solutions, and also took on several key positions leading Fitbit’s B2B efforts. Prior to Fitbit, Amy held strategic roles at CNET Networks, including Director of Audience and Content Development for the Community Division and Director of Strategic Partnerships for the Network. Amy has a bachelor’s degree from Merrimack College in Andover, MA and a Professional Certificate in Integrated Marketing Communications from the UC Berkeley Extension program. Amy used to run marathons, but today she gets her steps by chasing her two young boys around. They keep her busy enough to walk the equivalent of one full circle around the earth.

Dr. Andrey Ostrovsky was the former Chief Medical Officer of the US Medicaid program. He is the Managing Partner at Social Innovation Ventures where he invests in and advises companies, non-profits, and artists dedicated to eliminating disparities. He also advises federal and state regulators on how to incorporate human centered design into policy making. He previously operated a series of methadone clinics in Baltimore, Maryland. Prior to working on the front line of the opioid use disorder crisis, he served as the Chief Medical Officer for the Center for Medicaid and CHIP Services, the nation’s largest health insurer, where he advocated to protect the program against several legislative efforts to significantly dismantle the program. He also led efforts to streamline Medicaid and make it more customer-centric. Before leading the Medicaid program, he co-founded the software company, Care at Hand, an evidence-based predictive analytics platform that used insights of non-medical staff to prevent aging people from being hospitalized. Care at Hand was acquired in 2016 by Mindoula Health. Before Care at Hand, Dr. Ostrovsky led teams at the World Health Organization, United States Senate, and San Francisco Health Department toward health system strengthening. Dr. Ostrovsky has served on several boards and committees dedicated to behavioral health, interoperability standards, quality measurement, and home and community based services including the National Academies of Medicine, National Quality Forum, Institute for Healthcare Improvement, and the Commonwealth Fund.

Daniel Daugaard is the Founder and Co-CEO of Dawn Health. The digital health company was established in 2016 and has expanded at a rapid pace under his leadership with a purpose-driven vision to improve the lives of people living with chronic conditions. In the past two years, he and the Dawn Health team have raised substantial investments to deploy their product platform on a global scale, alongside a board of directors consisting of the highest caliber leaders from the tech and healthcare industry. In 2022, Dawn Health expanded its workforce with 350% and secured high growth fostered through strong industry partnerships with the world’s leading life sciences companies. With a legacy of high-impact product launches across +20 therapy areas internationally, Dawn Health is considered a catalyst for innovation within development and deployment of SaMD & DTx products with a clear aspiration that empowers patients to take control beyond the pill.

With over two decades of expertise, Kevin is a seasoned Information Technology Architect, Software Engineer, and Tech Leader. He has played a vital role in overseeing numerous projects, ranging from custom DTx and companion app development to integration services. At DTx East 2023, he will share his valuable insights on the challenges and pitfalls of integrating patient solutions, highlighting how NewPage Solutions can unlock the full potential of digital health solutions through their plug-and-play integration services.

Perry Wilson, MD MSCE is an Associate Professor of Medicine and Public Health at Yale University and Director of the Clinical and Translational Research Accelerator (CTRA) in the Department of Medicine.

Dr. Wilson grew up in Connecticut, before attending Harvard College where he graduated with honors in biochemistry. He then attended medical school at Columbia College of Physicians and Surgeons, before completing his internship, residency, and fellowship at the University of Pennsylvania. In 2012, he received a Masters degree in Clinical Epidemiology, which has informed his research ever since. At Yale since 2014, his goal is use patient-level data, advanced analytics, and digital health technolgies to personalize medicine to each individual patient. To that end he holds multiple NIH grants and is the Director of Yale’s Clinical and Translational Research Accelerator.

Dr. Wilson is internationally recognized for his expertise in design and interpretation of medical studies and has appeared in medpagetoday.com, medscape.com, the Huffington Post and the Milwaukee Journal Sentinel. His free online course, entitled “Understanding Medical Research: Your Facebook Friend Is Wrong” can be found on Coursera.org. His new book, “How Medicine Works and When it Doesn’t” was published by Hachette in January.

Alyssa Reisner is a Lead Director and Principal at CVS Health Ventures. In
her role, she sources, evaluates, and executes investments in innovative
health care companies. She has built strategic relationships and executed
investments for CVS Health in areas spanning DTx, women’s health,
behavioral health, COVID-19 initiatives, and more.

John is passionate about empowering patient communities to become active participants at
every stage of the clinical trial process. In his new role, John will lead and scale out our DCT
solutions and design the operational capabilities necessary to successfully deliver clinical trials
of the future to achieve top-line revenue growth. Working in collaboration with leaders within
digital, operations, product, strategy and commercial, as well as external partners, he will be
responsible for developing and implementing a robust, scalable strategy for the execution of
DCT trials – a core service line of our clinical trials business.
John has spent over a decade working at the intersection of clinical research and patient
advocacy. Prior to joining Walgreens, John was a member of the leadership team at Casimir, a
Contract Research Organization focused on the development and delivery of novel outcome
measures in decentralized clinical trials. At Casimir, John was head of business development
and study operations, delivering over 40 decentralized and hybrid studies in over 25 countries.
John is focused on using novel approaches to increase access, equity and diversity in clinical
trials and to improve the meaningfulness of clinical trial data. Prior to Casimir, John worked to
engage the patient voice in the clinical trial process as the head of communications for the Jett
Foundation, a nonprofit dedicated to funding research and programs for Duchenne muscular
dystrophy.
John holds a bachelor’s degree in government and English from Colby College. He is an
accomplished author and 2014 Jeopardy! champion. John will be based remotely in
Massachusetts.
Kendal and John are both well-respected clinical trial industry veterans who bring a wealth of
experience across decentralized trial development, business development, RWE, patient
empowerment and health equity. In the weeks to come, I will continue to elevate and expand
our team across Product, Clinical Delivery, Clinical Site Operations, Commercial and
RWE/Scientific Affairs to further accelerate our focus on create and deliver the next generation
of clinical trials for the industry.

Vijay Ravindran is the founder and CEO of Floreo, a virtual reality therapeutic for people with autism spectrum disorder, ADHD and anxiety.

Ravindran’s career spans digital commerce and news media. He joined Amazon in 1998 when the company sold books and music. He later served as director of the ordering department at Amazon and led the team that launched Amazon Prime. As Chief Digital Officer for The Washington Post Company, he founded WaPo Labs and oversaw the development of over a dozen products in digital news and launched Washington Post Social Reader and Trove, a personalized news web application.

He is an engineering graduate of the University of Virginia and serves on the Board of The Lenfest Institute for Journalism and Athanase Innovation AB.

As International Head, Patient Solutions & Services at Novartis, Anders leads the team charged with designing and delivering holistic patient experiences across all of their touchpoints with Novartis along the entire patient journey, whether through devices, Apps, Social Media, marketing campaigns, call centers or any other service. Previously, Anders served as the Global Head of Digital Health within Novartis Pharma. Prior to his time at Novartis, Anders held strategic roles at Optum, where he was VP for Strategy & Digital, and at Boston Children’s Hospital where he led Strategy & Digital Innovation, following a career in strategy consulting. Anders holds a bachelor’s degree from Copenhagen Business School, a master’s degree from the London School of Economics and an MBA from Columbia Business School.

Chuck is the lead for Simon-Kucher’s Digital Health practice in the US and has been advising companies for 14 years. Over the past 5 years, Simon-Kucher’s Digital Health practice has been continuously supporting numerous pharmaceutical companies that are invested in or considering investing in DTx. In addition, Simon-Kucher has also supported some of the leading VC-backed pure play DTx companies both in the US and ex-US on a variety of commercial strategy topics.

Dr. Joseph Cafazzo is the inaugural Wolfond Chair in Digital Health, Executive Director of Biomedical Engineering and Senior Scientist, for both The Centre for Digital Therapeutics and Healthcare Human Factors at the University Health Network. As a biomedical engineer, Dr. Cafazzo observes healthcare delivery from the inside-out and works on ways to keep people out of hospital by creating technologies that allow for self-care at home.

Over time, he has built an intricate network of clinicians, designers, engineers, researchers, that challenge the norms of healthcare and empower patients and their families. Together they push the boundaries of what’s possible, which has led to the creation of technologies that act to facilitate patient self-care of complex chronic conditions such as diabetes, asthma, end-stage renal disease and congestive heart failure.

Adriano leads clinical-first evidence generation and clinical validation programs for digital health, digital medicine and digital therapeutic products.

Adriano is a director in our Boston office in the evidence generation and outcomes research (EGOR) practice within ZS’s digital connected health group.

Adriano has more than 15 years of broad experience working in healthcare and medical device industries. He has hands-on experience supporting large clients in diverse domains such as evidence generation and outcomes research, business model transformation, market access and digital products commercialization.

Over the past four years, Adriano has led a number of client programs and accounts for top 100 pharma and medical device companies. He is focused on clinical validation and evidence generation for digital health and digital medicine products. Adriano has developed strategic alliances with academic medical partners for accelerated evidence generation and expedited market access. Additionally, he and his team support clients with pre-market submissions of software as a medical device to the FDA for marketing authorization in the U.S. and other global markets.

Adriano completed a five-year biotechnology engineering degree at Universidade Lusófona de Humanidades e Tecnologias in Portugal. He then earned a master’s degree in business administration from Bentley University in Massachusetts. Adriano has also completed advanced studies in public health, and in leadership and strategy for IT in healthcare from Harvard School of Public Health.

Dr. Risa Weisberg has devoted her career to developing and scientifically testing scalable interventions for common behavioral health problems. Her mission is to expand the reach of high-quality, science-based behavioral health treatment. She has over two decades of research, clinical, and leadership experience which she now brings to lead the clinical direction and research strategy of BehaVR at Chief Clinical Officer. Risa has a doctoral degree in Clinical Psychology from the University at Albany. She completed a doctoral internship and postdoctoral fellowship at Brown University. She is a Professor of Psychiatry at the Boston University School of Medicine and an Adjunct Professor of Family Medicine at the Alpert Medical School of Brown University. She is an expert in cognitive-behavioral therapy and acceptance and commitment therapies. As a primary care psychologist, Risa has broad experience in treatment development and implementation for common behavioral health problems including anxiety, depression, chronic pain, substance use disorder, and adaptation to living with other chronic medical difficulties. Her research has been funded by the National Institutes of Health, the Patient Centered Outcomes Research Institute, the Veterans Administration, and numerous foundations. Risa is a member of the Scientific Council of the Anxiety and Depression Association of America and a Fellow and former Board Member of the Association for Behavioral and Cognitive Therapies.

Linda Li joined Cleveland Clinic in 2022 as Partner focusing on Digital Health. She is responsible for the health tech investments and portfolio companies, particularly in artificial intelligence and machine learning-enabled clinical breakthrough technologies.

Prior to joining Cleveland Clinic, Linda was a Co-founding Partner of Vickers Venture Partner and an investment committee member where she oversaw investments in China, Southeast Asia, and the United States.

Linda is active in community volunteerism where she advocates for digital health, women and youth career growth. She serves on the board of CFA Society Shanghai and is an advisor to many incubators to promote startups with women leadership.

Linda graduated from Beijing University and subsequently earned her Master’s Degree from the National University of Singapore. She also holds a dual Bachelor of Arts in the German Language and is a CFA charter holder. She is a Kauffman Fellow (Class of ‘16) and is currently in a PhD program studying digital health and its implementation at Johns Hopkins University.

Erez Kaminski is the CEO and Founder of Ketryx Corporation, the first and only connected lifecycle management software for MedTech that unifies quality and R&D efforts to deliver safer, more innovative software 3x faster through the tools developers know and love. Over the last decade, Erez worked in industries including computational mathematics, biotech, and energy, helping build monitoring systems for pharmaceutical equipment and AI for medication management. Erez is deeply concerned with improving patient care and health outcomes with software solutions.

Anish has 13+ years in Health, and
Digital Therapeutics. Sales & Marketing is his
core strength for driving
adoption of new tech
trends for top line or
bottom-line impact. Executed 23 Bio-Pharma
partnerships &
collaborations; 5 CVC
investments within
HealthTech companies in
the past 6 years. Recently he started his
venture, GSD Health, with
partners that share the
same purpose of “Making
startups Investable &
Successful”

As Head of Clinical Domain Strategy and Partnerships for Elevance Health, Sophie
Clarke, MD., is responsible for thoughtfully guiding the company to drive improved
clinical outcomes, affordability, access, and experience through both internally delivered
and partnership-supported clinical programs.
Sophie is responsible for driving Elevance Health’s Maternal and Child Health, Adult
Health, and Oncology strategies, evaluating and recommending strategic clinical
partnerships, and delivering comprehensive Disease Management programs to
Elevance Health’s Commercial and Medicaid populations.
Before joining Elevance Health in June 2020, Sophie was an Engagement Manager at
McKinsey & Company where she provided strategic and operational counsel to a wide
range of healthcare clients including providers, payers, philanthropic organizations, and
state governments.
Sophie received her M.D. from the Icahn School of Medicine at Mount Sinai and her B.A
from Middlebury College. A mother of two under two, she and her husband reside in
Cambridge, Massachusetts.

Dr. Saemundur “Sam” Oddsson is one of two co-founders of Sidekick Health, a rapidly growing digital health company that is transforming disease management in over a dozen countries by building meaningful partnerships with global pharmaceutical companies and large payers and providers in the US. With a background in clinical research, digital innovation, and practicing internal medicine & cardiology as a medical doctor, Sam has been at the forefront of the fight against some of the world’s most devastating diseases as a medical doctor, innovative entrepreneur & thought leader, including partnering on Pres. Joe Bidens CancerX Moonshot initiative in the US

Jordan Glenn, Ph.D., is the Chief Science Officer of Neurotrack. He has developed a diverse background in the digital health space where he has used his expertise in exercise, nutrition, aging and behavior change to focus on disease states such as diabetes, cardiovascular disease, and now Alzheimer’s and dementia. As Neurotrack’s Chief Science Officer, he leads the company’s scientific pipeline, while also informing the company’s business development/ partnerships. He also holds an academic dual-appointment at the University of Arkansas and has been authored on over 80 scientific publications. He is also the primary investigator on the DC-MARVEL project, which is the first study ever to investigate the effects of fully remote, digital health coaching on Alzheimer’s disease risk.

In February 2023, Glenn delivered Neurotrack’s winning pitch in the Alzheimer’s Association Pitch Competition, aimed at identifying innovations to increase cognitive assessment and early detection and diagnosis of dementia within primary care settings.

Eugene is a serial intra and entrepreneur, executive, venture builder, speaker & board advisor
with a focus in digital health. Eugene is a Co-Founder and COO at YourCoach Health.

Frank has almost 3 decades of experience in the financial and life-sciences sectors, helping build companies that successfully developed and commercialized multiple products. He has a long standing passion for the intersection of medical science and digital technology and how it can be applied to improve human health. Prior to Better Therapeutics, Frank was President and Chief Financial Officer of Myovant Sciences where he led the company’s efforts to raise approximately $2 billion in capital and its evolution from a private start-up organization to a publicly listed commercial stage company with two marketed products. He also served as Executive Vice President and Chief Financial Officer at Exelixis, Inc. for over a decade, as the company evolved from a discovery to a commercial organization.

Diane has more than two decades experience in the medtech, consumer care and pharmaceutical sectors with significant experience in P&L management, operations, multichannel distribution, and marketing. Diane spent 17 years in the MedTech sector at Johnson & Johnson, ascending through strategic and commercial roles. While there, she oversaw specialty areas including plastic and reconstructive surgery, biosurgery, interventional cardiology, neurovascular, and peripheral vascular, ultimately holding the title of Worldwide President, Mentor. Diane went on to serve as U.S. President for Galderma, an integrated dermatology company across aesthetics, consumer care and prescription medicines where she led a major transformation for the company and delivered double-digit growth.

Dr Renae Beaumont is an award-winning child and adolescent psychologist who is the founder of the video-gaming based program Secret Agent Society (SAS). SAS is an evidence-based skills training framework that has been shown to improve the emotion regulation skills, social skills and behavior of eight- to twelve-year-old children with Autism, ADHD and Anxiety Disorders. To date, the lives of over 25 000 children and families in nine countries worldwide have been touched by SAS. Originally from Australia, Dr Beaumont moved to the US seven years ago, where she is a faculty member and clinician at Weill Cornell Medicine, New York Presbyterian Hospital. Dr Beaumont is passionate about using technologically innovative approaches to improve the mental health and wellbeing of youth and families.